Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Revisiting acquired aplastic anaemia: Current concepts in diagnosis and management.

Clucas D, Fox LC, Wood EM, Hong FS, Gibson J, Bajel A, Szer J, Blombery P, McQuilten ZK, Hiwase D, Firkin F, Cole-Sinclair MF; Australian Aplastic Anaemia Registry Steering Committee.

Intern Med J. 2018 Oct 15. doi: 10.1111/imj.14140. [Epub ahead of print] Review.

PMID:
30324755
2.

Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma.

Radivoyevitch T, Dean RM, Shaw BE, Brazauskas R, Tecca HR, Molenaar RJ, Battiwalla M, Savani BN, Flowers MED, Cooke KR, Hamilton BK, Kalaycio M, Maciejewski JP, Ahmed I, Akpek G, Bajel A, Buchbinder D, Cahn JY, D'Souza A, Daly A, DeFilipp Z, Ganguly S, Hamadani M, Hayashi RJ, Hematti P, Inamoto Y, Khera N, Kindwall-Keller T, Landau H, Lazarus H, Majhail NS, Marks DI, Olsson RF, Seo S, Steinberg A, William BM, Wirk B, Yared JA, Aljurf M, Abidi MH, Allewelt H, Beitinjaneh A, Cook R, Cornell RF, Fay JW, Hale G, Chakrabarty JH, Jodele S, Kasow KA, Mahindra A, Malone AK, Popat U, Rizzo JD, Schouten HC, Warwick AB, Wood WA, Sekeres MA, Litzow MR, Gale RP, Hashmi SK.

Leuk Res. 2018 Nov;74:130-136. doi: 10.1016/j.leukres.2018.07.016. Epub 2018 Jul 19.

PMID:
30055822
3.

The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients.

Willcox A, Wong E, Nath C, Janson B, Harrison SJ, Hoyt R, Bajel A, Shaw P, Ritchie D, Grigg A.

Ann Hematol. 2018 Dec;97(12):2509-2518. doi: 10.1007/s00277-018-3447-x. Epub 2018 Jul 26.

PMID:
30051172
4.

MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML.

Sanders MA, Chew E, Flensburg C, Zeilemaker A, Miller SE, Al Hinai AS, Bajel A, Luiken B, Rijken M, Mclennan T, Hoogenboezem RM, Kavelaars FG, Fröhling S, Blewitt ME, Bindels EM, Alexander WS, Löwenberg B, Roberts AW, Valk PJM, Majewski IJ.

Blood. 2018 Oct 4;132(14):1526-1534. doi: 10.1182/blood-2018-05-852566. Epub 2018 Jul 26.

5.

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States.

Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, Aljurf M, Ballen KK, Bajel A, Baron F, Battiwalla M, Beitinjaneh A, Cahn JY, Carabasi M, Chen YB, Chhabra S, Ciurea S, Copelan E, D'Souza A, Edwards J, Foran J, Freytes CO, Fung HC, Gale RP, Giralt S, Hashmi SK, Hildebrandt GC, Ho V, Jakubowski A, Lazarus H, Luskin MR, Martino R, Maziarz R, McCarthy P, Nishihori T, Olin R, Olsson RF, Pawarode A, Peres E, Rezvani AR, Rizzieri D, Savani BN, Schouten HC, Sabloff M, Seftel M, Seo S, Sorror ML, Szer J, Wirk BM, Wood WA, Artz A.

Blood. 2017 Aug 31;130(9):1156-1164. doi: 10.1182/blood-2017-03-772368. Epub 2017 Jul 3.

6.

An individualised risk-adapted protocol of pre- and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation: results of a phase II prospective trial.

Grigg A, Butcher B, Khodr B, Bajel A, Hertzberg M, Patil S, D'Souza AB, Ganly P, Ebeling P, Wong E.

Bone Marrow Transplant. 2017 Sep;52(9):1288-1293. doi: 10.1038/bmt.2017.108. Epub 2017 Jun 19.

PMID:
28628088
7.

A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia.

Verstovsek S, Courby S, Griesshammer M, Mesa RA, Brachmann CB, Kawashima J, Maltzman JD, Shao L, Xin Y, Huang D, Bajel A.

Leuk Res. 2017 Sep;60:11-17. doi: 10.1016/j.leukres.2017.05.002. Epub 2017 May 30.

8.

A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.

Ho PJ, Bajel A, Burbury K, Dunlop L, Durrant S, Forsyth C, Perkins AC, Ross DM.

Intern Med J. 2017 Mar;47(3):262-268. doi: 10.1111/imj.13341.

PMID:
28260257
9.

Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia.

Liu HD, Ahn KW, Hu ZH, Hamadani M, Nishihori T, Wirk B, Beitinjaneh A, Rizzieri D, Grunwald MR, Sabloff M, Olsson RF, Bajel A, Bredeson C, Daly A, Inamoto Y, Majhail N, Saad A, Gupta V, Gerds A, Malone A, Tallman M, Reshef R, Marks DI, Copelan E, Gergis U, Savoie ML, Ustun C, Litzow MR, Cahn JY, Kindwall-Keller T, Akpek G, Savani BN, Aljurf M, Rowe JM, Wiernik PH, Hsu JW, Cortes J, Kalaycio M, Maziarz R, Sobecks R, Popat U, Alyea E, Saber W.

Biol Blood Marrow Transplant. 2017 May;23(5):767-775. doi: 10.1016/j.bbmt.2017.01.078. Epub 2017 Jan 20.

10.

GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes.

Chen YB, Wang T, Hemmer MT, Brady C, Couriel DR, Alousi A, Pidala J, Urbano-Ispizua A, Choi SW, Nishihori T, Teshima T, Inamoto Y, Wirk B, Marks DI, Abdel-Azim H, Lehmann L, Yu L, Bitan M, Cairo MS, Qayed M, Salit R, Gale RP, Martino R, Jaglowski S, Bajel A, Savani B, Frangoul H, Lewis ID, Storek J, Askar M, Kharfan-Dabaja MA, Aljurf M, Ringden O, Reshef R, Olsson RF, Hashmi S, Seo S, Spitzer TR, MacMillan ML, Lazaryan A, Spellman SR, Arora M, Cutler CS.

Bone Marrow Transplant. 2017 Mar;52(3):400-408. doi: 10.1038/bmt.2016.265. Epub 2016 Dec 12.

11.

Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience.

Jeong W, Haywood P, Shanmuganathan N, Lindsay J, Urbancic K, Ananda-Rajah MR, Chen SC, Bajel A, Ritchie D, Grigg A, Seymour JF, Peleg AY, Kong DC, Slavin MA.

J Antimicrob Chemother. 2016 Dec;71(12):3540-3547. Epub 2016 Aug 11.

PMID:
27521358
12.

Nephrotic syndrome as a complication of chronic graft-versus-host disease after allogeneic haemopoietic stem cell transplantation.

Wong E, Lasica M, He SZ, Bajel A, Roberts AW, Mason KD, Ritchie DS, Szer J.

Intern Med J. 2016 Jun;46(6):737-41. doi: 10.1111/imj.13098.

PMID:
27257151
13.

Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma.

Thompson PA, Perera T, Marin D, Oran B, Popat U, Qazilbash M, Shah N, Parmar S, Rezvani K, Olson A, Kebriaei P, Anderlini P, Rondon G, Alousi A, Ciurea S, Champlin RE, Bajel A, Szer J, Shpall EJ, Ritchie D, Hosing CM.

Leuk Lymphoma. 2016 Jul;57(7):1607-15. doi: 10.3109/10428194.2015.1105370. Epub 2015 Dec 23.

PMID:
26472485
14.

Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014.

Fleming S, Yannakou CK, Haeusler GM, Clark J, Grigg A, Heath CH, Bajel A, van Hal SJ, Chen SC, Milliken ST, Morrissey CO, Tam CS, Szer J, Weinkove R, Slavin MA.

Intern Med J. 2014 Dec;44(12b):1283-97. doi: 10.1111/imj.12595. Review.

PMID:
25482741
15.

Australian consensus guidelines for the safe handling of monoclonal antibodies for cancer treatment by healthcare personnel.

Alexander M, King J, Bajel A, Doecke C, Fox P, Lingaratnam S, Mellor JD, Nicholson L, Roos I, Saunders T, Wilkes J, Zielinski R, Byrne J, MacMillan K, Mollo A, Kirsa S, Green M.

Intern Med J. 2014 Oct;44(10):1018-26. doi: 10.1111/imj.12564.

PMID:
25302720
16.

Validating the allogeneic stem cell transplantation disease risk index: sample size, follow-up, and local data are important.

Lim AB, Roberts AW, Mason K, Bajel A, Szer J, Ritchie DS.

Transplantation. 2015 Jan;99(1):128-32. doi: 10.1097/TP.0000000000000257.

PMID:
25102305
17.

Screening with spirometry is a useful predictor of later development of noninfectious pulmonary syndromes in patients undergoing allogeneic stem cell transplantation.

Thompson PA, Lim A, Panek-Hudson Y, Tacey M, Hijazi R, Ng AP, Szer J, Ritchie D, Bajel A.

Biol Blood Marrow Transplant. 2014 Jun;20(6):781-6. doi: 10.1016/j.bbmt.2014.02.011. Epub 2014 Feb 16.

18.

Central nervous system multiple myeloma--potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chains.

Lee D, Kalff A, Low M, Gangatharan S, Ho P, Bajel A, Ritchie D, Grigg A, Spencer A.

Br J Haematol. 2013 Aug;162(3):371-5. doi: 10.1111/bjh.12404. Epub 2013 May 29.

PMID:
23718539
19.

Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial.

Morrissey CO, Chen SC, Sorrell TC, Milliken S, Bardy PG, Bradstock KF, Szer J, Halliday CL, Gilroy NM, Moore J, Schwarer AP, Guy S, Bajel A, Tramontana AR, Spelman T, Slavin MA; Australasian Leukaemia Lymphoma Group and the Australia and New Zealand Mycology Interest Group.

Lancet Infect Dis. 2013 Jun;13(6):519-28. doi: 10.1016/S1473-3099(13)70076-8. Epub 2013 Apr 30.

PMID:
23639612
20.

Rituximab is associated with improved survival for aggressive B cell CNS lymphoma.

Gregory G, Arumugaswamy A, Leung T, Chan KL, Abikhair M, Tam C, Bajel A, Cher L, Grigg A, Ritchie D, Opat S.

Neuro Oncol. 2013 Aug;15(8):1068-73. doi: 10.1093/neuonc/not032. Epub 2013 Mar 15.

21.

Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.

Heng SC, Slavin MA, Al-Badriyeh D, Kirsa S, Seymour JF, Grigg A, Thursky K, Bajel A, Nation RL, Kong DC.

J Antimicrob Chemother. 2013 Jul;68(7):1669-78. doi: 10.1093/jac/dkt068. Epub 2013 Mar 13.

PMID:
23485723
22.

Disseminated toxoplasmosis after allogeneic stem cell transplantation in a seronegative recipient.

Osthoff M, Chew E, Bajel A, Kelsey G, Panek-Hudson Y, Mason K, Szer J, Ritchie D, Slavin M.

Transpl Infect Dis. 2013 Feb;15(1):E14-9. doi: 10.1111/tid.12043. Epub 2012 Dec 20.

PMID:
23279790
23.

Impact of palifermin on mucosal toxicity in autologous stem cell transplants using busulfan-melphalan conditioning chemotherapy for Hodgkin and non-Hodgkin lymphoma.

Campbell P, Friebe A, Foulstone P, Grigg A, Hempton J, Bajel A.

Leuk Lymphoma. 2012 Jul;53(7):1415-6. doi: 10.3109/10428194.2011.653639. Epub 2012 Jan 31. No abstract available.

PMID:
22204452
24.

Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.

Ananda-Rajah MR, Grigg A, Downey MT, Bajel A, Spelman T, Cheng A, Thursky KT, Vincent J, Slavin MA.

Haematologica. 2012 Mar;97(3):459-63. doi: 10.3324/haematol.2011.051995. Epub 2011 Nov 4.

25.

Lymphocyte vacuolation: clue to inherited metabolic disease.

Bajel A, Bazargan A, Doery J, Roy S.

Pathology. 2010 Dec;42(7):699-700. doi: 10.3109/00313025.2010.523694. No abstract available.

PMID:
21080890
26.

A case of plasmablastic lymphoma harbouring an IgH/MYC translocation in a HIV negative individual.

McGlaughlin KL, Bajel A, Mow CD.

Pathology. 2010 Dec;42(7):697-9. doi: 10.3109/00313025.2010.523693. No abstract available.

PMID:
21080889
27.

Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia.

Al-Badriyeh D, Slavin M, Liew D, Thursky K, Downey M, Grigg A, Bajel A, Stewart K, Kong DC.

J Antimicrob Chemother. 2010 May;65(5):1052-61. doi: 10.1093/jac/dkq076. Epub 2010 Mar 17.

PMID:
20237074
28.

IgA nephropathy associated with cutaneous T cell lymphoma.

Bajel A, Yin Lin M, Hill PA, Goodman D, McCormack C, Foley P, Davison J, Hönemann D, Kenealy M, Lade S, Ryan G, Prince HM.

Leuk Lymphoma. 2009 Dec;50(12):2083-5. doi: 10.3109/10428190903288472. No abstract available.

PMID:
19863174
29.

Frequency of TPMT alleles in Indian patients with acute lymphatic leukemia and effect on the dose of 6-mercaptopurine.

Desire S, Balasubramanian P, Bajel A, George B, Viswabandya A, Mathews V, Srivastava A, Chandy M.

Med Oncol. 2010 Dec;27(4):1046-9. doi: 10.1007/s12032-009-9331-8. Epub 2009 Oct 15.

PMID:
19830600
30.

Bone marrow metastasis in gastro-intestinal stromal tumour.

Bajel A, Simpson I, Longano A, Roy S, Richardson G.

Br J Haematol. 2009 Oct;147(1):2. doi: 10.1111/j.1365-2141.2009.07735.x. Epub 2009 May 26. No abstract available.

PMID:
19545287
31.

Aplastic anaemia: autoimmune sequel of thymoma.

Bajel A, Ryan A, Roy S, Opat SS.

Br J Haematol. 2009 Dec;147(5):591. doi: 10.1111/j.1365-2141.2009.07716.x. Epub 2009 May 5. No abstract available.

PMID:
19438484
32.

Iron homeostasis: new players, newer insights.

Edison ES, Bajel A, Chandy M.

Eur J Haematol. 2008 Dec;81(6):411-24. doi: 10.1111/j.1600-0609.2008.01143.x. Epub 2008 Sep 13. Review.

PMID:
18754855
33.

Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol.

Bajel A, George B, Mathews V, Viswabandya A, Kavitha ML, Srivastava A, Chandy M.

Pediatr Blood Cancer. 2008 Nov;51(5):621-5. doi: 10.1002/pbc.21671.

PMID:
18688848
34.

Safe treatment of a patient with CML using dasatinib after prior retinal oedema due to imatinib.

Bajel A, Bassili S, Seymour JF.

Leuk Res. 2008 Nov;32(11):1789-90. doi: 10.1016/j.leukres.2008.03.027. Epub 2008 May 6. No abstract available.

PMID:
18462793
35.

Adult ALL: treatment outcome and prognostic factors in an Indian population using a modified German ALL (GMALL) protocol.

Bajel A, George B, Mathews V, Viswabandya A, Kavitha ML, Srivastava A, Chandy M.

Leukemia. 2007 Oct;21(10):2230-3. Epub 2007 Jun 7. No abstract available.

PMID:
17554379
36.

Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity.

Mathews V, Desire S, George B, Lakshmi KM, Rao JG, Viswabandya A, Bajel A, Srivastava VM, Srivastava A, Chandy M.

Leukemia. 2006 May;20(5):881-3. No abstract available.

PMID:
16525498
37.

Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity.

Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, Shaji RV, Srivastava VM, Srivastava A, Chandy M.

Blood. 2006 Apr 1;107(7):2627-32. Epub 2005 Dec 13.

Supplemental Content

Support Center